Jan. 17 at 4:45 PM
$EYPT EyePoint Pharmaceuticals (EYPT) shares have seen recent positive news, including a significant premarket surge on January 16, 2026, following FDA approval for its Yutiq implant for uveitis, alongside analyst upgrades and continued optimism for its pipeline, especially the DURAVYU Phase 3 trials for wet AMD, with topline data expected mid-2026. The company also granted new employee stock options, reflecting growth, though it remains unprofitable, with strong analyst ratings and price targets pointing to substantial upside.
Key Recent Developments
FDA Approval (Jan 16, 2026): U.S. FDA approved the Yutiq implant for treating uveitis, causing a stock jump.
Phase 3 Trial Update (Nov 2025): A Data Safety Monitoring Committee recommended continuing pivotal trials for DURAVYU (wet AMD) with positive safety findings, with 56-week data due mid-2026.
Analyst Sentiment: Strong "Buy" ratings and high price targets (around
$36+) suggest significant potential upside.
